Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $15.55 Average Price Target from Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has earned an average recommendation of “Hold” from the thirteen ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $15.3889.

A number of research firms have recently weighed in on FOLD. The Goldman Sachs Group raised their price target on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Jefferies Financial Group restated a “hold” rating and set a $14.50 target price (down from $16.00) on shares of Amicus Therapeutics in a report on Thursday, January 22nd. Needham & Company LLC cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 19th. Citigroup reaffirmed a “neutral” rating and issued a $14.50 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Monday, December 22nd. Finally, Guggenheim downgraded Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th.

Insiders Place Their Bets

In other news, insider Ellen Rosenberg sold 23,621 shares of the business’s stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $10.00, for a total value of $236,210.00. Following the completion of the sale, the insider directly owned 507,710 shares in the company, valued at approximately $5,077,100. The trade was a 4.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Michael Clark sold 25,642 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $14.17, for a total transaction of $363,347.14. Following the sale, the insider directly owned 245,690 shares of the company’s stock, valued at approximately $3,481,427.30. This represents a 9.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 242,419 shares of company stock valued at $2,947,172 over the last 90 days. 2.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Amicus Therapeutics by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 29,702,696 shares of the biopharmaceutical company’s stock valued at $422,966,000 after acquiring an additional 168,667 shares during the period. William Blair Investment Management LLC lifted its position in shares of Amicus Therapeutics by 7.6% during the 3rd quarter. William Blair Investment Management LLC now owns 15,749,240 shares of the biopharmaceutical company’s stock worth $124,104,000 after purchasing an additional 1,107,083 shares during the last quarter. HBK Investments L P bought a new stake in Amicus Therapeutics during the 4th quarter valued at approximately $217,160,000. State Street Corp grew its holdings in Amicus Therapeutics by 28.3% in the 4th quarter. State Street Corp now owns 14,833,314 shares of the biopharmaceutical company’s stock valued at $211,226,000 after buying an additional 3,270,375 shares during the last quarter. Finally, Vestal Point Capital LP increased its position in Amicus Therapeutics by 178.4% in the 2nd quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock worth $68,187,000 after buying an additional 7,625,000 shares during the period.

Amicus Therapeutics Trading Up 0.1%

Shares of NASDAQ FOLD opened at $14.36 on Thursday. The business has a 50 day simple moving average of $14.09 and a 200 day simple moving average of $10.50. Amicus Therapeutics has a 52 week low of $5.51 and a 52 week high of $14.38. The stock has a market cap of $4.51 billion, a price-to-earnings ratio of -179.50 and a beta of 0.38. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.09 and a current ratio of 2.99.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.03). The business had revenue of $185.21 million for the quarter, compared to the consensus estimate of $185.00 million. Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.47%. Amicus Therapeutics’s revenue was up 23.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.09 EPS. On average, research analysts predict that Amicus Therapeutics will post 0.15 earnings per share for the current fiscal year.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.